HIV drug resistance can affect how effectively antiretroviral medicines control viral replication. It occurs when genetic changes in HIV reduce the activity of one or more medicines. Understanding resistance is important because treatment depends on selecting combinations of medicines that remain active against the virus. Inhibitor based therapies, including integrase strand transfer inhibitors.
HIV treatment has changed substantially with the development of potent antiretroviral medicines. Antiretroviral therapy works by targeting different stages of the HIV life cycle, limiting viral replication and allowing the immune system to recover or remain protected. The objective of treatment is sustained viral suppression, generally measured through HIV RNA viral load testing. However, HIV can develop genetic changes that reduce susceptibility to particular medicines, creating drug resistance. The World Health Organization reports that all current antiretroviral drug classes can potentially be affected by resistance, although the likelihood and patterns differ among medicines.
HIV drug resistance occurs when changes in the virus reduce the ability of an antiretroviral medicine to inhibit viral replication. Resistance may be present before treatment begins, known as pretreatment resistance, or may develop during treatment. Inadequate drug exposure can provide opportunities for resistant variants to become more prominent. Factors associated with inadequate exposure can include missed doses, interruptions in treatment, drug interactions, difficulties obtaining medicines, or an ineffective regimen. WHO emphasizes adherence, viral load testing, and timely management of treatment failure as important elements in limiting resistance.
Important aspects of HIV drug resistance include:
Resistance does not necessarily mean that all HIV medicines will stop working. Different medicines act on different viral targets, and treatment can be adjusted according to resistance results, previous treatment history, viral load, and other clinical considerations.
Inhibitor based therapy refers to antiretroviral treatment that includes medicines designed to inhibit specific proteins or processes required for HIV replication. One important group is integrase strand transfer inhibitors, or INSTIs. These medicines interfere with HIV integrase, an enzyme needed for incorporating viral genetic material into the DNA of an infected cell.
Dolutegravir is an INSTI that has become a major component of recommended HIV treatment. WHO's updated 2026 clinical management recommendations continue to identify dolutegravir based regimens as preferred options for initial and subsequent treatment, while also providing approaches for people whose existing regimens are no longer effective.
The role of inhibitor based treatment includes:
WHO reports that more than 90 percent of patients receiving dolutegravir based treatment achieve sustained viral suppression when treatment is taken consistently. At the same time, surveillance has identified emerging dolutegravir resistance among some people with unsuppressed viral loads, particularly those with extensive previous treatment experience.
Viral load testing is central to evaluating whether antiretroviral therapy is controlling HIV replication. HIV RNA and CD4 cell counts provide important information about treatment response and immune function. When virologic failure is suspected, resistance testing can help determine whether mutations are contributing to reduced treatment effectiveness. NIH guidance recommends resistance testing to help guide antiretroviral regimen selection and recommends including integrase testing when INSTI resistance is a concern.
Maintaining effective suppression involves:
Sustained viral suppression reduces the opportunity for HIV to replicate and acquire additional resistance mutations. For people experiencing treatment failure, timely evaluation can help identify the reason for detectable viral load and determine whether the regimen needs modification.
HIV drug resistance and inhibitor based therapy are closely connected to the long term effectiveness of antiretroviral treatment. Resistance can limit the activity of individual medicines, while appropriately selected combinations can continue to suppress HIV despite previous treatment exposure. Modern inhibitor based regimens, particularly those containing integrase strand transfer inhibitors, have become important tools in HIV care. Continued adherence, viral load monitoring, resistance testing when appropriate, and individualized clinical management remain important for maintaining viral suppression and preserving future treatment options.